ERBB2 and breast carcinoma: Therefore, as suggested by our cases, the hormone-based strategy as primary treatment in locally advanced, inoperable diseases could be considered as a significant option not only in patients considered unfit for chemotherapy but also in all those patients who were affected by a low-proliferative, HR+, HER2-, breast cancer.